Fintel Short Squeeze Leaderboard Identifies Short Squeeze Opportunities for Traders
Fintel’s short interest data identifies candidates for the week of May 1, 2022
Stay updated with breaking news from Zymeworks Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fintel’s short interest data identifies candidates for the week of May 1, 2022
By Anirban Sen (Reuters) -Investment firm All Blue Capital has approached Zymeworks Inc, a developer of antibody therapies for cancer, with a $773 mil...
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday. Following the market opening Friday, the D...
Vancouver-based Zymeworks Receives US $773 Million (Non-Binding) Acquisition Offer From All Blue Falcons FZE, Stock Pops 36%. Vancouver, BC, April 29, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, confirmed that it has received an unsolicited, non-binding acquisition proposal from All Blue Falcons FZE ("ABF") and its affiliates to purchase the Company for $10.50 per share in cash.
Equities analysts expect that Zymeworks Inc. (NYSE:ZYME – Get Rating) will post sales of $3.76 million for the current quarter, according to Zacks. Four analysts have issued estimates for Zymeworks’ earnings, with the highest sales estimate coming in at $6.00 million and the lowest estimate coming in at $1.75 million. Zymeworks posted sales of $640,000.00 […]